Sign in →

Test ID: SSA SS-A/Ro Antibodies, IgG, Serum

Reporting Name

SS-A/Ro Ab, IgG, S

Useful For

Evaluating patients with signs and symptoms of a connective tissue disease in whom the test for antinuclear antibodies is positive

 

Testing for SS-A/Ro antibodies is not useful in patients without demonstrable antinuclear antibodies.

Clinical Information

SS-A/Ro is an extractable nuclear antigen (ENA) composed of protein antigens of 52 kD and 60 kD combined with cytoplasmic RNA species. SS-A/Ro antibodies occur in patients with several different connective tissue diseases including Sjogren syndrome, an autoimmune disease that involves primarily the salivary and lachrymal glands (up to 90% of cases); lupus erythematosus (LE) (40%-60% of cases); and rheumatoid arthritis. SS-A/Ro antibodies are associated with childhood LE, neonatal LE, and with congenital heart block in infants born to mothers with LE.(1,2) SS-A/Ro antibodies have also been reported to be associated with features of extraglandular inflammation in patients with LE including vasculitis, purpura, cytopenias, and adenopathy.

 

SS-A/Ro is 1 of 4 autoantigens commonly referred to as extractable nuclear antigens (ENA). The other ENA are SS-B/La, RNP, and Sm. Each ENA is composed of 1 or more proteins associated with small nuclear or cytoplasmic RNA species (snRNP) ranging in size from 80 to 350 nucleotides. Antibodies to ENA are common in patients with connective tissue diseases (systemic rheumatic diseases) including LE, mixed connective tissue disease, Sjogren syndrome, scleroderma (systemic sclerosis), and polymyositis/dermatomyositis.

 

See Connective Tissue Disease Cascade (CTDC) in Special Instructions.

Interpretation

A positive result for SS-A/Ro antibodies is consistent with connective tissue disease, including Sjogren syndrome, lupus erythematosus (LE), or rheumatoid arthritis.

 

A positive result for SS-A/Ro antibodies in a woman with LE prior to delivery indicates an increased risk of congenital heart block in the neonate.

Testing Algorithm

See Connective Tissue Disease Cascade (CTDC) in Special Instructions.

Analytic Time

1 day

Day(s) and Time(s) Performed

Monday through Saturday; 4 p.m.

Clinical Reference

1. Homburger H, Larsen S: Detection of specific antibodies. In Clinical Immunology: Principles and Practice. First edition. Edited by R Rich, T Fleisher, B Schwartz, et al. St. Louis, Mosby-Year Book, 1996, pp 2096-2109

2. Kotzin B, West S: Systemic lupus erythematosus. In Clinical Immunology Principles and Practice. Second edition. Edited by R Rich, T Fleisher, W Shearer, et al. St. Louis, Mosby-Year Book 2001, pp 60.1-60.24

Method Name

Multiplex Flow Immunoassay

Specimen Type

Serum


Specimen Required


Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Specimen Volume: 0.5 mL


Specimen Minimum Volume

0.35 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 21 days
  Frozen  21 days

Reference Values

<1.0 U (negative)

≥1.0 U (positive)

Reference values apply to all ages.

Test Classification

This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

86235

LOINC Code Information

Test ID Test Order Name Order LOINC Value
SSA SS-A/Ro Ab, IgG, S 33610-7

 

Result ID Test Result Name Result LOINC Value
SSA SS-A/Ro Ab, IgG, S 33610-7
Mayo Clinic Laboratories | Neurology Catalog Additional Information:

mml-Behavioral, mml-Epilepsy, mml-Headache, mml-Movement-Disorders, mml-Demyelinating-Diseases, mml-Neuroimmunology, mml-Neuromuscular, mml-Autonomic, mml-Pediatric, mml-Spinal-Cord, mml-Neuro-ophthalmology